— Approximately 12% growth year-over-year in revenues —
— Greater than $555 million in cash, cash equivalents, marketable securities, and restricted cash —
— Cash burn continued its declining trend over the past five quarters —
— Presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 9:00 a.m. PST —
SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced preliminary unaudited fourth quarter and full-year 2022 revenue, cash burn and commercial metrics.
Preliminary, unaudited financial results and other metrics for 2022
Generated revenue of approximately $516 million in 2022, or about a 12% increase from $460 million in 2021. Fourth quarter 2022 revenue was approximately $122 million, versus $126 million a year ago, which reflects a decline due to the exited businesses and geographies.
Cash, cash equivalents, restricted cash and marketable securities were greater than $555 million as of December 31, 2022. Our cash burn in the fourth quarter was less than $80 million, which excludes an outflow of approximately $10 million related to realignment and an inflow of approximately $45 million related to the selected assets sale of the RUO kitted solutions. This represents a continued declining trend since the fourth quarter of 2021.
Total active healthcare provider accounts of approximately 20,000, an increase of 8% from 2021.
Active pharma and commercial partnerships grew to approximately 230, an increase of 29% in 2022, due to revenue growth from lab services, data services to pharmaceutical, health systems and other partners.
Total patient population is more than 3.6 million with over 62% available for data sharing.
“Despite a challenging environment in 2022, we executed well against our realignment plan in the second half of the year, with continued improvements in our financial metrics and cash burn reduction. Overall, we are pleased with our progress and with the hard work across the organization that has driven these results,” said Ken Knight, president and chief executive officer of Invitae. “The mission of Invitae has not changed, and we are committed to bringing genetics to mainstream medicine. Our company is also building on a new foundation grounded on achieving profitable growth. And as we move forward, we’re excited about what lies ahead for our company, our partners and millions more patients. We’re looking forward to our opportunities in 2023 and beyond, unlocking the value that Invitae holds.”
Invitae has not completed preparation of its financial statements for the fourth quarter or full year 2022. The preliminary, unaudited results presented in this press release for the year ended December 31, 2022, are based on current expectations and are subject to adjustment. Actual results may differ materially from those disclosed in this press release. Invitae will report its full financial results and other metrics during its fourth quarter and year-end 2022 conference call in late February.
Invitae’s Presentation at 41st Annual J.P. Morgan Healthcare Conference
Invitae will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 12:00 p.m. Eastern Time / 9:00 a.m. Pacific Time. A live webcast of both the presentation and a Q&A session may be accessed at the following direct link or by visiting the investors section of the company’s website at ir.invitae.com. Public listeners can access an audio and slide recording of the session, which will be available shortly after the conclusion of the presentation and Q&A session on the investors section of the company’s website at ir.invitae.com.
About Invitae
Invitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae’s genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
To learn more, visit invitae.com
Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s mission; the expected impact, benefits, and timing of the company’s strategic business realignment or various aspects thereof; the company’s beliefs regarding the potential of its business, and its business priorities and initiatives and the potential benefits thereof; the company’s future financial and operating results, and the drivers of future financial results; 2022 preliminary financial results, including revenue and cash burn; the company’s roadmap and product pipeline; and the company’s beliefs regarding its business and its comprehensive offerings. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: actual results for the fourth quarter and full year 2022, the year-end close process and audit of the company’s financial statements; the ability of the company to successfully execute its strategic business realignment and achieve the intended benefits thereof on the expected timeframe or at all; unforeseen or greater than expected costs associated with the strategic business realignment; the risk that the disruption that may result from the realignment may harm the company’s business, market share or its relationship with customers or potential customers; the impact of COVID-19 on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the impact of inflation and the current economic environment on the company’s business; the company’s ability to grow its business in a cost-efficient manner; the company’s history of losses; the company’s ability to maintain important customer relationships; the company’s ability to compete; the company’s failure to manage growth effectively; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the applicability of clinical results to actual outcomes; risks associated with litigation; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; laws and regulations applicable to the company’s business; and the other risks set forth in the reports filed by the company with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Non-GAAP Financial Measures
To supplement the company’s consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP), the company is providing several non-GAAP measures. These non-GAAP financial measures exclude certain items that are required by GAAP. In addition, these non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-GAAP financial measures are useful to investors in evaluating the company’s ongoing operating results and trends. Management uses such non-GAAP information to manage the company’s business and monitor its performance.
Other companies, including companies in the same industry, may not use the same non-GAAP measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. Because of these limitations, the company’s non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the non-GAAP reconciliations provided in the tables below and on the company’s website.
Contacts for Invitae:
Investor Relations
Hoki Luk
ir@invitae.com
Public Relations
Amy Hadsock
pr@invitae.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-reports-preliminary-2022-financial-results-301716138.html
SOURCE Invitae Corporation
Related Quotes
Image source: Getty Images Many retailers have been negatively impacted by the pandemic and recent bout of rampant inflation. And Bed Bath & Beyond is one of them. The home goods giant recently acknowledged that its days of operations may be limited.
Cancer-testing company Exact Sciences hadn’t expected to report cash profits until this year’s September quarter. Sales of screening products like the Cologuard stool test for colorectal cancer jumped more than 40%. Shares of Exact Sciences (ticker: EXAS) jumped nearly 19% to $56.12.
Eon Productions, the company behind the James Bond films, posted revenues of £234.7 million ($285.5 million) for the financial period covering the initial release of “No Time To Die,” its latest accounts show. The accompanying financial report also shows that the company is already focused on the next instalment of the Bond franchise, albeit one […]
Yahoo Finance Live anchors discuss the decline in stock for Illumina after the company issued weaker-than-expected guidance for 2023.
Bed Bath & Beyond see some volatile action ahead of its earnings this week.
MercadoLibre (MELI) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Millennials are more apt to step in and buy equities during sell-offs, according to data compiled by TD Ameritrade.
Shares of Teladoc Health Inc. (TDOC) rallied about 9% in trading on Monday after the company said in a securities filing that it narrowed revenue guidance for 2022 to $2.403 billion to $2.410 billion, from $2.395 billion to $2.410 billion, matching the FactSet consensus of $2.400 billion in sales for the year. William Blair analysts said the narrowed guidance is a “positive announcement.” Teladoc plans to share additional information about its fiscal performance during a presentation on Monday morning at the annual J.P. Morgan Healthcare Conference.
The Cambridge gene-editing company is laying off 20% of its workforce as it cuts drug programs geared toward retinal diseases and solid tumors.
Yahoo Finance Live anchors discuss the rise in stock for Bed Bath & Beyond following third-quarter earnings.
CrowdStrike (NASDAQ: CRWD) went public at $34 a share in June 2019. The cloud-based cybersecurity company's stock started trading at $63.50, and it eventually soared to an all-time high of $293.18 in November 2021. The bears believe CrowdStrike is due for a breather following years of breakneck growth.
‘Should we be redecorating, going to Cancun and Disney World and getting takeout every night instead?’
We are yet to find out what lies in store for the stock market in 2023. However, we do know that the previous year was one of the worst ever, with the S&P 500 putting in its 7th most abject annual performance since 1929. Whichever way you look at it, then, most investors did not enjoy the past 12 months’ market action. One positive takeaway, however, is that the overall bearish trend has driven share prices down across the board and that has left some stocks at levels that are now just too cheap
Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) has one of the most closely followed stock portfolios in the world. The conglomerate owns about four dozen stocks, with a combined market value of more than $325 billion, and many of the positions were chosen by legendary investor Warren Buffett himself. Here's what they are, and why they're my favorite "Buffett stocks" for the long term.
What happened Shares of Novocure (NASDAQ: NVCR) are sinking today, down by 15.4% as of 10:44 a.m. ET. The decline came after the company announced its preliminary full-year and fourth-quarter 2022 net revenue numbers.
Palantir (NYSE: PLTR) and Salesforce (NYSE: CRM) both own cloud-based platforms that gather and analyze large amounts of data to help their clients make smarter decisions. Analysts expect Salesforce to generate $31 billion in revenue in its fiscal 2023 year (which ends this month), or more than 16 times the $1.9 billion in revenue Palantir was expected to generate in 2022. Let's review Palantir's approach to data mining, how much larger it could grow, and if it could evolve into a blue-chip cloud giant like Salesforce in the future.
The shares of the producer of fuel cell systems for on-site power generation could go higher but the technical evidence isn't convincing at this stage.
There's not much point in buying a passive-income stock like AbbVie (NYSE: ABBV) if it's going to fail to deliver its quarterly dividend into your account. As it turns out, there is indeed a risk that within the next few years, AbbVie's shareholders get left high and dry instead of getting refreshed with cash as usual. AbbVie just celebrated its 10th birthday since its spinoff from Abbott Laboratories at the start of 2013.
With the Nasdaq Composite falling 33% in the year, it might have seemed like every time you bought a stock, it fell 20%, 30%, or more in the following weeks. For reference, if you invested $10,000 in the Nasdaq Composite at the beginning of 2009, you would have over $65,300 today — even after the drop in 2022. Shares of Datadog (NASDAQ: DDOG) got crushed in 2022, falling nearly 59%.
According to data from S&P Global Market Intelligence, the stock has fallen by 62% since the S&P 500 peaked on Jan. 3, 2022. Could the cruise line operator's shares make a comeback in 2023? All cruises were put on hold in the early stages of the pandemic, and while those ships have now resumed sailing, operators including Carnival, the world's biggest cruise line operator, have struggled to recover from their extended pause.
Invitae Reports Preliminary 2022 Financial Results – Yahoo Finance
